News | November 10, 2025
AstraZeneca delivers double-digit growth
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
AI-powered cardiometabolic wellness platform for India’s workforce
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
